JINS HOLDINGS (3046) Fundamentals 2026 — P/E 18.4x, Revenue Analysis | SniperIQ
JINS HOLDINGS (3046) is a JP-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥152.7B, trading at ¥6540.00 on the JPX. This SniperIQ fundamentals page covers JINS HOLDINGS's valuation (P/E 18.4x, P/B 4.3x), profitability (net margin 7.7%), revenue (¥97.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is JINS HOLDINGS's market cap?
JINS HOLDINGS (3046) has a market capitalization of approximately ¥152.7B, trading at ¥6540.00 on the JPX. Market cap moves with the live share price.
What is JINS HOLDINGS's P/E ratio?
JINS HOLDINGS's trailing twelve-month P/E ratio is 18.4x, with a price-to-book (P/B) of 4.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is JINS HOLDINGS?
JINS HOLDINGS runs a net profit margin of 7.7%, a gross margin of 78.4%, and an operating margin of 11.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does JINS HOLDINGS generate?
JINS HOLDINGS reported revenue of ¥97.2B for fiscal year 2025, with net income of ¥8.3B and earnings per share (EPS) of 356.88. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does JINS HOLDINGS pay a dividend?
JINS HOLDINGS offers a trailing dividend yield of about 1.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is JINS HOLDINGS financially healthy?
JINS HOLDINGS carries a debt-to-equity ratio of 0.22x and a current ratio of 1.26x, with a market beta of 0.35. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is JINS HOLDINGS a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For JINS HOLDINGS (3046) the key facts are: market cap ¥152.7B, P/E 18.4x, revenue ¥97.2B, 52-week range 4920-10330. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track JINS HOLDINGS's full fundamentals live
Get JINS HOLDINGS's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.